Global Neuroendocrine Tumors Market is expected to grow with the CAGR of 10.4% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-neuroendocrine-tumors-market
Global neuroendocrine tumors market is a highly consolidated market which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in global neuroendocrine tumors market are introducing strong range of product portfolio. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in August 2020, F. Hoffmann-La Roche Ltd had announced that the European Commission had granted priority approval for marketing authorization for Rozlytrek for treatment of adult and children aged 12 years suffering from advanced non-small cell lung cancer. The approval received is based on the cumulative analysis of phase II clinical trials, STARTRK-2. The approval received by the company would result in rise in research collaborations, timely treatment of the individuals and rise in revenue. It would exhibit a positive growth in the market.
F. Hoffmann-La Roche Ltd is the dominating player in global neuroendocrine tumors market. The other key players existing in the neuroendocrine tumors market includes Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG), BioSynthema Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Bionano Genomics, callistopharma, Illumina, Inc., GlaxoSmithKline plc, Hutchison China MediTech Limited among others.
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd is headquartered in Basel, Switzerland and was founded in 1896. The company is focused on development of innovative medicines and diagnostic tests that help patients survive longer and better lives. The company deals in multiple business segments such as pharmaceuticals, diagnostics and corporate among which pharmaceuticals is the market focused segment. The company provides products under categories such as oncology, immunology, opthalmology, infectious diseases, cardiometabolism, neuroscience and other among which oncology is the market focused category.
The company has presence in Americas, Europe, Africa, Asia-Pacific and Middle East and Africa. The company generates its revenue through various subsidiaries such as Genentech (U.S), Chugai Pharmaceutical Co. (Japan), ROCHE HOLDING (UK) LIMITED (U.K.), Roche (Philippines) Inc. (Philippines), Roche Chile Limitada (Chile) among others.
Bristol-Myers Squibb Company:
Bristol-Myers Squibb Company is headquartered in New York, U.S. and was founded in 1887. The company is focused on discovering, developing and delivering transformational medicines in areas where the company believes, it has an opportunity to make a meaningful difference for patients dealing with oncology, immunoscience, cardiovascular and fibrosis. The company deals in multiple business segments such as Orencia, other, total pharmaceuticals and prioritized brands among which prioritized brands is the market focused segment. The company provides products under categories such as medical, aesthetic, surgical abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), azactam (aztreonam for injection, usp), breyanzi (lisocabtagene maraleucel), baraclude (entecavir), droxia (hydroxyurea), eliquis (apixaban), empliciti (elotuzumab), evotaz (atazanavir and cobicistat), hydrea (hydroxyurea), idhifa (enasidenib), inrebic (fedratinib), istodax (romidepsin), kenalog-10 (triamcinolone acetonide), nulojix (belatacept), onureg (azacitidine tablets), opdivo (nivolumab), orencia (abatacept), pravachol (pravastatin sodium), pomalyst (pomalidomide), reblozyl (luspatercept-aamt) among which opdivo (nivolumab), hydrea (hydroxyurea), ipilimumab, cabozanitinib are the market focused categories.
The company has wide global presence across North America, Europe, Asia-Pacific and Middle East and Africa. The company has various subsidiaries namely Bristol-Myers Squibb Investco, L.L.C (U.S.), Bristol-Myers Squibb Luxembourg International S.C.A. (Luxembourg), Bristol-Myers Squibb Marketing Services S.R.L. (Germany) among others.
Viatris Inc. is headquartered in Pennsylvania, U.S. and was founded in 2020. The company is focused on delivery of increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance. The company offers wide range of products under categories such as brands, generics, biosimilars, over-the-counter products and active pharmaceutical ingredients among which biosimilars is the market focused category.
The company has wide global presence across Americas, Europe and Asia-Pacific. The company various subsidiaries namely Rottapharm | Madaus GmbH (Germany), MEDA Pharma GmbH and Co. KG (Germany), Merck Generics Belgium B.V.B.A. (Belgium), Arcana Arzneimittel GmbH (Germany), Mylan Laboratories India Private Ltd (India) among others.
Global Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028
Asia-Pacific Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028
Europe Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028
Middle East and Africa Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028
North America Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028